| CAS NO: | 165538-40-9 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| Cas No. | 165538-40-9 |
| 别名 | 特鲁曲班,Terutroban,Triplion |
| 化学名 | (6R)-6-[[(4-chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-2-methyl-1-naphthalenepropanoic |
| Canonical SMILES | CC1=C(CCC(O)=O)C2=C(C=C1)C[C@H](NS(C3=CC=C(Cl)C=C3)(=O)=O)CC2 |
| 分子式 | C20H22ClNO4S |
| 分子量 | 407.9 |
| 溶解度 | ≤2mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | IC50: 16.4 nM for TP receptor S18886 is a potent thromboxane A2 (TP) inhibitor. The lipid mediator thromboxane A2 (TXA2) plays a critical role in platelet aggregation and vascular and bronchial smooth muscle constriction. The actions of TXA2 are mediated via the specific G protein coupled-receptor, TXA2 receptor (TP). In vitro: S18886 was identified as the active isomer of the potent TP receptor antagonist S18204. S18886 was also found to be a selective antagonist of thromboxaneprostaglandin receptors in platelets and in the vessel wall [1]. In vivo: In a previous animal study, it was found that S18886 treatment could reduce the portal pressure in both animal models without producing significant changes in portal blood flow, indicating a reduction in hepatic vascular resistance. S18886 could not significantly change arterial pressure in CCl4 -cirrhotic rats but could significantly decrease it in BDL-cirrhotic rats [2]. Clinical trial: A previoius trial aiming to evaluate S18886 versus aspirin in patients with cerebral ischaemic events showed similar rates of the primary endpoint with S18886 and aspirin, without safety advantages for S18886 [3]. References: |
m.cnreagent.com